Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 3/20 | 0.81 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8720672 | 0.98 | KAT2B (0.78) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6198359 | 0.98 | KAT2B (0.78) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7170020 | 0.96 | KAT2B (0.81) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6198859 | 0.92 | KAT2B (0.80) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11295216 | 0.92 | KAT2B (0.69) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1170743 | 0.92 | KAT2B (0.69) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7745271 | 0.92 | KAT2B (0.69) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14220312 | 0.90 | KAT2B (0.88) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7970498 | 0.90 | KAT2B (0.68) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11380052 | 0.90 | KAT2B (0.68) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020202091-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-08 | — | — | WO | disclosed |
| EP-1091942-B1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH AS (DK) | 2005-03-30 | — | — | EP | disclosed |
| US-6569880-B2 | Guanidine derivatives | NEUROSEARCH A/S (DK) | 2003-05-27 | — | — | US | disclosed |
| US-20020137784-A1 | Potassium channel blocking agents | NEUROSEARCH A/S | 2002-09-26 | — | — | US | disclosed |
| US-6380180-B1 | BENZIMIDAZOLE COMPOUNDS FOR TREATMENT OF ASTHMA, VASOSPASM, MEMORY LOSS, MIGRAINE AND OTHERS DISEASES ASSOCIATED WITH POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2002-04-30 | — | — | US | disclosed |
| US-20020049246-A1 | Potassium channel blocking agents | NEUROSEARCH A/S | 2002-04-25 | — | — | US | disclosed |
| EP-1091942-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2001-04-18 | — | — | EP | disclosed |
| US-6194447-B1 | ASTHMA, ANTICONVULSANTS, COGNITION ACTIVATORS, BRAIN DISORDERS, PSYCHOLOGICAL DISORDERS, CARDIOVASCULAR DISORDERS,GASTROINTESTINAL DISORDERS | NEUROSEARCH A/S (DK) | 2001-02-27 | — | — | US | disclosed |
| WO-2000001676-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2000-01-13 | — | — | WO | disclosed |
| WO-1995030658-A1 | DIMERIC BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINERGIC AGENTS, ESP. SELECTIVE FOR THE DOPAMINE D3 RECEPTOR | WARNER-LAMBERT COMPANY (US) | 1995-11-16 | — | — | WO | disclosed |
| US-5414010-A | Dopaminergic blocking agents and psychotic depression | WARNER-LAMBERT COMPANY (US) | 1995-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137784-A1 | Potassium channel blocking agents | KCNH2, KCNH3, KCND2 | KAT2B 851/4885MAPT 918/4885NPC1 770/4885 |
| US-20020049246-A1 | Potassium channel blocking agents | KCNH2, KCNH3, KCND2 | KAT2B 851/4885MAPT 918/4885NPC1 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.